SKI Market

A+| A| A-|

Indian Indices

Sensex

78,493.54 504.86
( 0.65%)

Global Indices

Nasdaq

49,467.44 867.71
(1.79%)

Dow Jones

7,146.92 84.64
(1.20%)

Hang Seng

58,837.37 -680.97
(-1.14%)

Nikkei 225

10,660.47 70.48
(0.67%)

Forex

USD-INR

93.19 -0.12
(-0.13%)

EUR-INR

109.85 -0.18
(-0.16%)

GBP-INR

126.25 -0.31
(-0.25%)

JPY-INR

0.59 0.00
(-0.15%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Shanti Educational Initiatives Ltd

Industry : Miscellaneous

BSE Code

ISIN Demat

Book Value()

539921

INE440T01028

4.6742733

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

N.A

2870.63

EPS(TTM)

Face Value()

Div & Yield %

0.24

Back

mahindra & mahindra ltd

Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets

Apr 08,2026

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo® XR for the indications in the approved labeling.

78,493.54 504.86 ( 0.65%)

49,467.44 867.71 (1.79%)

7,146.92 84.64 (1.20%)

58,837.37 -680.97 (-1.14%)

10,660.47 70.48 (0.67%)

93.19 -0.12 (-0.13%)

109.85 -0.18 (-0.16%)

126.25 -0.31 (-0.25%)

0.59 0.00 (-0.15%)